WASHINGTON, DC / ACCESS Newswire / May 8, 2026 / A growing conflict between international scientific findings and U.S. healthcare policy is raising urgent questions about whether Medicare beneficiaries are being exposed to cannabinoid products that have not been proven safe.
In March 2026, the European Food Safety Authority (EFSA) issued a formal scientific rejection of Charlottes Web hemp product submission concluding that the safety of a carbon dioxide extract derived from Cannabis sativa L. – including products associated with leading U.S. brands – “cannot be established.”
That conclusion was not based on politics. It was based on data.
According to EFSA, critical gaps included:
-
Significant portions of the product remaining uncharacterized
-
Lack of reliable toxicological studies on the actual material
-
Absence of human clinical data
-
Unknown allergenicity and long-term safety profile
The agency’s bottom line was clear:
The safety of the product could not be determined.
Meanwhile in the United States
At nearly the same time, the Centers for Medicare & Medicaid Services (CMS) launched the Substance Access Beneficiary Engagement Incentive (BEI) program.
The initiative allows participating healthcare providers to discuss and furnish certain hemp, marijuana derived cannabinoid products to Medicare beneficiaries under Innovation Center authority.
Unlike traditional drug pathways, the BEI program does not require approval from the U.S. Food and Drug Administration.
That distinction is central to a federal lawsuit now pending:
Smart Approaches to Marijuana (SAM), et al. v. Robert F. Kennedy Jr., et al.
Case No. 1:26-cv-01081 (U.S. District Court for the District of Columbia)
The Scientific Gap
Under the FDA framework, products intended for therapeutic use typically undergo:
-
Controlled clinical trials
-
Dose standardization
-
Safety and toxicology evaluation
-
Manufacturing and stability validation
The BEI program operates outside that structure.
While CMS has described the initiative as an innovation model, critics argue it effectively introduces products into federally funded care environments before those scientific benchmarks are met.
Why This Matters for Seniors
Medicare beneficiaries represent one of the most medically complex populations in the healthcare system.
Many patients:
-
Take multiple medications (polypharmacy)
-
Have chronic conditions
-
Are more vulnerable to drug interactions
